PRTC

Puretech Health

• Benzinga·15h ago

  12 Health Care Stocks Moving In Friday's After-Market Session

• TipRanks·04/02 12:36

  PureTech Health announces publication of Phase 2b ELEVATE IPF trial results

• Benzinga·04/02 12:31

  PureTech Health Publishes Data From Phase 2b ELEVATE IPF Study Of Deupirfenidone To Treat Idiopathic Pulmonary Fibrosis

• Reuters·04/02 12:19

  PURETECH ANNOUNCES PUBLICATION OF PHASE 2B ELEVATE IPF TRIAL RESULTS IN THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

• TipRanks·04/02 11:47

  PureTech founded Seaport announces topline results from GlyphAgo trial

• Benzinga·04/02 11:19

  PureTech's Founded Entity, Seaport Therapeutics, Announces Topline Data From Portions Of Ongoing Phase 1 Proof-Of-Concept Clinical Trial Evaluating GlyphAgo

• Reuters·04/02 11:08

  PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ANNOUNCES POSITIVE PROOF OF CONCEPT TOPLINE RESULTS FROM ONGOING PHASE 1 TRIAL OF GLYPHAGO™ IN HEALTHY VOLUNTEERS

• Benzinga·03/25 18:09

  PureTech Health's Seaport Therapeutics Announces Publication Of First-In-Human Clinical And Preclinical Data For GlyphAllo In Science Translational Medicine

• Reuters·03/24 11:03

  Camp4 appoints Michael MacLean to board, expands board to nine directors

• TipRanks·02/19 17:50

  PureTech Health announces orphan drug designation for Deupirfenidone in IPF

• Benzinga·02/19 17:38

  PureTech Health Announces That The FDA And European Commission Have Granted Orphan Drug Designation To Deupirfenidone For The Treatment Of Idiopathic Pulmonary Fibrosis

• Reuters·02/19 17:36

  PureTech Wins FDA and EU Orphan Drug Designations for Deupirfenidone in IPF

• Reuters·02/19 17:36

  PURETECH ANNOUNCES ORPHAN DRUG DESIGNATIONS GRANTED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN COMMISSION FOR DEUPIRFENIDONE (LYT-100) IN IDIOPATHIC PULMONARY FIBROSIS

• Reuters·02/12 12:02

  Compugen Appoints Michele Holcomb to Board of Directors

• Seeking Alpha·12/18/2025 10:18

  PureTech names Robert Lyne as CEO